Kou Junyan, Huang Jing, Li Jun, Wu Zhen, Ni Liwei
Department of Oncology, Hangzhou Cancer Hospital, Hangzhou, 310000, Zhejiang, People's Republic of China.
Clin Exp Med. 2023 Nov;23(7):3895-3905. doi: 10.1007/s10238-023-01035-y. Epub 2023 Mar 26.
The systemic immune-inflammation index (SII) is a significant prognostic factor in some cancer types. However, the prognostic role of SII in cancer patients with immunotherapy remains uncertain. We aimed to evaluate the relationship between pretreatment SII and clinical survival outcomes for advanced-stage cancer patients treated with immune checkpoint inhibitors (ICIs). A comprehensive literature search was performed to identify eligible studies concerning the association between pretreatment SII and survival outcomes in advanced cancer patients treated with ICIs. The data were extracted from publications and used to calculate the pooled odds ratio (pOR) for objective response rate (ORR), disease control rate (DCR), and pooled hazard ratio (pHR) for overall survival (OS), progressive-free survival (PFS), along with 95% confidence intervals (95% CIs). Fifteen articles with 2438 participants were included. A higher level of SII indicated a lower ORR (pOR = 0.73, 95% CI 0.56-0.94) and worse DCR (pOR = 0.56, 95% CI 0.35-0.88). High SII was associated with a shorter OS (pHR = 2.33, 95% CI 2.02-2.69) and unfavorable PFS (pHR = 1.85, 95% CI 1.61-2.14). Therefore, high SII level might be a non-invasive and efficacious biomarker of poor tumor response and adverse prognosis of advanced cancer patients with immunotherapy.
全身免疫炎症指数（SII）是某些癌症类型中的一个重要预后因素。然而，SII在接受免疫治疗的癌症患者中的预后作用仍不确定。我们旨在评估晚期癌症患者接受免疫检查点抑制剂（ICI）治疗前SII与临床生存结果之间的关系。进行了全面的文献检索，以确定关于晚期癌症患者接受ICI治疗前SII与生存结果之间关联的合格研究。数据从出版物中提取，并用于计算客观缓解率（ORR）、疾病控制率（DCR）的合并比值比（pOR），以及总生存期（OS）、无进展生存期（PFS）的合并风险比（pHR），并给出95%置信区间（95%CI）。纳入了15篇文章，共2438名参与者。较高水平的SII表明ORR较低（pOR = 0.73，95%CI 0.56 - 0.94）和DCR较差（pOR = 0.56，95%CI 0.35 - 0.88）。高SII与较短的OS（pHR = 2.33，95%CI 2.02 - 2.69）和不良的PFS（pHR = 1.85，95%CI 1.61 - 2.14）相关。因此，高SII水平可能是晚期癌症免疫治疗患者肿瘤反应不佳和预后不良的一种非侵入性有效生物标志物。
